Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. (NASDAQ: REVB) is a clinical-stage life sciences company developing Gemini, a proprietary PHAD®-based toll-like receptor 4 (TLR4) agonist designed to rebalance the innate immune response in acute and chronic inflammation-driven diseases. The REVB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow key scientific, clinical, regulatory, and corporate developments.
News about Revelation Biosciences frequently highlights progress across its Gemini programs for acute kidney injury (GEMINI-AKI), chronic kidney disease (GEMINI-CKD), prevention of post-surgical infection (GEMINI-PSI), and treatment of severe burn-related hyperinflammation (GEM-PBI). Updates include clinical milestones such as Phase 1 and Phase 1b data from the PRIME study in stage 3 and 4 CKD patients, where the company has reported safety, reductions in inflammatory activity, and restoration of normal cellular responses to stimuli.
Investors and observers can also find announcements about interactions with the U.S. Food and Drug Administration, including submission and acceptance of an end-of-phase 1 meeting package for Gemini in AKI, as well as manufacturing news such as the start of GMP production of Gemini and placebo to support later-stage randomized, double-blinded, placebo-controlled trials.
Beyond clinical and regulatory updates, the REVB news stream covers financial and corporate actions disclosed by the company, including warrant exercise inducement transactions, special meetings of stockholders to approve share issuances under Nasdaq rules, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). Bookmark this page to monitor Revelation Biosciences’ ongoing disclosures about Gemini’s development, capital markets activity, and governance events.
Revelation Biosciences (NASDAQ:REVB) announced that its former chairman and shareholder, Dr. George Tidmarsh, has been appointed to head the FDA Center for Drug Evaluation and Research. Dr. Tidmarsh, who serves as an Adjunct Professor at Stanford University School of Medicine, has over three decades of biotech innovation experience and has successfully guided multiple medications through FDA approval.
Additionally, the company recently completed dosing in its PRIME Phase 1b clinical study of Gemini, investigating escalating doses administered intravenously in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).
Revelation Biosciences (NASDAQ: REVB) has completed patient dosing in its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study. The trial evaluated escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).
The study successfully enrolled 5 cohorts across 3 U.S. clinics. Multiple data sets are expected in Q3 2025, including safety parameters, hematologic changes, inflammatory response evaluation, and biomarker activity. The company plans to engage with the FDA to discuss future clinical development and approval pathways later in 2025.
Revelation Biosciences (NASDAQ: REVB) has announced a 1-for-3 reverse stock split effective July 7, 2025, following stockholder approval on June 23, 2025. The reverse split aims to increase the stock price to regain compliance with Nasdaq Capital Market's minimum bid listing requirements.
The company will maintain its trading symbol "REVB" with a new CUSIP number 76135L705. Proportionate adjustments will be made to conversion and exercise prices of warrants, restricted stock units, stock options, and shares under equity incentive plans. Additionally, REVB announced that enrollment for its PRIME Phase 1b clinical study of Gemini in CKD patients is expected to complete this month, with topline data anticipated shortly after.
Stockholders will see their shares automatically converted, with fractional shares rounded down. No action is required from registered stockholders or those holding shares through brokers.
Revelation Biosciences (NASDAQ: REVB) announced the retirement of George F. Tidmarsh, MD, PhD from its Board of Directors. Dr. Tidmarsh, who served on the board for 5 years, is stepping down to avoid potential conflicts of interest as he takes on new responsibilities working with US governmental agencies in his role as Adjunct Professor of Pediatrics and Neonatology at Stanford University School of Medicine. CEO James Rolke expressed gratitude for Dr. Tidmarsh's guidance and support during his tenure.
Revelation Biosciences (NASDAQ: REVB) has announced plans to develop its Gemini Platform for preventing infections in severe burn patients requiring hospitalization (GEM-PBI program). This initiative builds upon their existing work on preventing post-surgical infections (GEM-PSI program).
The company is collaborating with Vanderbilt University, from whom they previously licensed the patent family. Dr. Julia Bohannon, Associate Professor at Vanderbilt, reported that Gemini's clinical biomarker activity aligns with their preclinical infection burn models. Research shows the treatment reduces pseudomonas lung infection severity and duration while lowering overall inflammation levels.
CEO James Rolke emphasized that this expansion into burn patient care complements Revelation's existing work, noting that the Gemini-PBI program may present new opportunities in regulatory approval, development, and funding.
Revelation Biosciences (NASDAQ: REVB) announced positive results from a study showing that Gemini effectively reduces inflammation in human peripheral blood mononuclear cells (PBMCs). The study demonstrated that Gemini-primed PBMCs, when exposed to inflammatory promoters HMGB-1 and LPS, showed significantly decreased proinflammatory cytokines and increased anti-inflammatory cytokines compared to placebo.
The company is currently conducting a Phase 1b PRIME clinical study in patients with Stage 3 and 4 Chronic Kidney Disease (CKD), with top-line data expected by mid 2025. This data will include safety, tolerability, and cellular-level protection assessment, supporting future development of GEM-CKD, GEM-AKI, and GEM-PSI programs.
Revelation Biosciences (NASDAQ: REVB), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, has announced its participation in the 37th Annual Roth Conference. James Rolke, the company's Chief Executive Officer, will engage in a fireside chat scheduled for Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.
The event will be accessible through a live webcast and will subsequently be available for viewing in the Investors section of Revelation's website at www.RevBiosciences.com. Interested investors can arrange meetings with the management team through their Roth representatives.